TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. (RNAZ) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RNAZ · as of Sep 30, 2025
Ownership Breakdown
7
Institutional Holders
▼ 1 vs Q2
$155,012
Total Inst. Value
▼ $81,969 vs Q2
950,301
Shares Outstanding
freeFloat 87.91%
14,426
13F Shares Held
▼ 15,956 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RNAZ largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
DRW SECURITIES, LLC pharmaceutical preparations | 11.7K | 1.40% | 1.40% | $125.80M | Nov 14, 2025 | NEW |
CITIGROUP INC pharmaceutical preparations | 1.6K | 19.02% | 19.02% | $16.99M | Nov 10, 2025 | NEW |
FEDERATION DES CAISSES DESJARDINS DU QUEBEC pharmaceutical preparations | 975 | 11.70% | 11.70% | $10.48M | Nov 14, 2025 | NEW |
TOWER RESEARCH CAPITAL LLC (TRC) pharmaceutical preparations | 142 | 1.70% | 1.70% | $1.53M | Nov 14, 2025 | ▼ 260 |
SBI SECURITIES CO., LTD. pharmaceutical preparations | 10 | 0.12% | 0.12% | $108,000 | Nov 5, 2025 | — held |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 8 | 0.10% | 0.10% | $86,000 | Feb 3, 2026 | — held |
ADVISOR GROUP HOLDINGS, INC. pharmaceutical preparations | 3 | 0.04% | 0.04% | $29,000 | Nov 14, 2025 | — held |
UBS GROUP AG pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 13, 2025 | EXIT |
GOLDMAN SACHS GROUP INC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 14, 2025 | EXIT |
FMR LLC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 13, 2025 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
0
Increased
+0 shares3
New Positions
first time holders1
Decreased
−260 shares4
Sold Out
fully exitedNet shares change (top 50)
260
+0 / −260
Net new holders
-2
3 new / 4 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RNAZ insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
12
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Marquet Magda director | Jun 14, 2024 | Award | 70,000 | $1.20 | $84.0K | 70.0K | Form 4 ↗ |
Manting Erik director | Jun 14, 2024 | Award | 70,000 | $1.20 | $84.0K | 70.0K | Form 4 ↗ |
Fitzgerald Thomas A Interim CEO, CFO | Jun 14, 2024 | Award | 650,000 | $1.20 | $780.0K | 650.0K | Form 4 ↗ |
Calais Philippe director | Jun 14, 2024 | Award | 70,000 | $1.20 | $84.0K | 70.0K | Form 4 ↗ |
Fitzgerald Thomas A Chief Financial Officer | Sep 28, 2023 | Purchase | 49,350 | $0.51 | $25.2K | 56.3K | Form 4 ↗ |
Dudley Robert Michael Chief Executive Officer | Sep 28, 2023 | Purchase | 98,000 | $0.51 | $50.0K | 180.3K | Form 4 ↗ |
Dudley Robert Michael Chief Executive Officer | Jun 21, 2023 | Purchase | 12,000 | $2.65 | $31.8K | 82.3K | Form 4 ↗ |
Dudley Robert Michael Chief Executive Officer | Jun 20, 2023 | Purchase | 6,607 | $2.55 | $16.8K | 70.3K | Form 4 ↗ |
Dudley Robert Michael Chief Executive Officer | Jun 9, 2023 | Purchase | 19,000 | $2.76 | $52.4K | 61.2K | Form 4 ↗ |
Dudley Robert Michael Chief Executive Officer | Jun 9, 2023 | Purchase | 19,000 | $2.76 | $52.4K | 912.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
TransCode Therapeutics, Inc. (RNAZ) is primarily owned by institutional investors, who hold approximately 1.5% of total shares outstanding. Company insiders own approximately 12.09%, while retail and public investors account for the remaining 86.39%.
The largest institutional shareholder of TransCode Therapeutics, Inc. is DRW SECURITIES, LLC, holding approximately 11,702 shares — equal to 1.40% of outstanding shares — as of September 30, 2025.
A total of 7 institutional investors currently hold RNAZ stock, with a combined institutional value of approximately $155,012 as of the most recent 13F filing period.
Frequently asked questions
RNAZ ownershipTransCode Therapeutics, Inc. (RNAZ) is primarily owned by institutional investors, who hold approximately 1.5% of shares. The largest shareholder is DRW SECURITIES, LLC with a 1.40% stake. Company insiders hold 12.09%. Data sourced from SEC Form 13F as of September 30, 2025.